Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
CAMBRIDGE, Mass., April 19, 2016 -- Jounce Therapeutics, Inc., a company focused on the discovery and development of novel cancer immunotherapies coupled to patient enrichment strategies, today announced that Deborah Law, D. Phil., chief scientific officer, will be featured as a keynote speaker at Cambridge Healthtech Institute’s 12th Annual Protein Engineering Summit (PEGS) Boston during the Plenary Keynote Session on Monday, April 25, 2016 at 4 p.m. ET. The conference is being held April 25-29, 2016 at the Seaport World Trade Center in Boston.
In addition to the keynote, Dr. Law will present an overview of Jounce’s lead inducible T cell co-stimulator (ICOS) program, JTX-2011. Details of the presentation are as follows:
Date & Time: April 29, 2016 at 9:05 a.m. ET
Session: Emerging Agonists and Antagonist Targets
Title: Preclinical Evaluation of JTX-2011, an Anti-ICOS Agonist Antibody
About Jounce Therapeutics
Jounce Therapeutics is an immuno-oncology company dedicated to transforming the treatment of cancer. The company is discovering and developing novel cancer immunotherapies designed to harness the immune system to attack tumors and provide long-lasting benefits to patients. Jounce integrates translational science insights, including identification of related biomarkers, designed to match the right immunotherapy to the right patients. The company is advancing programs that leverage contributions from its world-class founders, as well as knowledge acquired from Jounce’s Translational Science Platform, to create a sustainable “discovery to human proof-of-concept” product engine with the potential to drive significantly more durable responses to treatment. Founded by world leaders in tumor immunology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures. For more information, please visit www.jouncetx.com.
Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected]
